Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

Journal of Clinical Oncology

Volumn 34, Issue 14, 2016, Pages 1601-1610

  Ribi, Karin ^a   Luo, Weixiu ^c,d   Bernhard, Jürg ^a   Francis, Prudence A ^i,j   Burstein, Harold J ^d,e   Ciruelos, Eva ^l   Bellet, Meritxell ^m   Pavesi, Lorenzo ^p   Lluch, Ana ⁿ   Visini, Marilena ^q   Parmar, Vani ^v   Tondini, Carlo ^r   Kerbrat, Pierre ^w,x   Perelló, Antonia ^o   Neven, Patrick ^x,y   Torres, Roberto ^z   Lombardi, Davide ^s   Puglisi, Fabio ^t   Karlsson, Per ^aa   Ruhstaller, Thomas ^b   Colleoni, Marco ^u   Coates, Alan S ^k   Goldhirsch, Aron ^a,u   Price, Karen N ^c,f   Gelber, Richard D ^c,d,f,g   Regan, Meredith M ^c,d,g   Fleming, Gini F ^h   more..

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c International Breast Cancer Study Group Statistical Center   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Alliance for Clinical Trials in Oncology   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF SYDNEY   (Australia)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^p IRCCS   (Italy)

^q Ospedale Civile   (Italy)

^r PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^s CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^t UNIVERSITY HOSPITAL OF UDINE   (Italy)

^u EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^v TATA MEMORIAL HOSPITAL   (India)

^w UNIVERSITÉ DE RENNES 1   (France)

^x EORTC DATA CENTER   (Belgium)

^y UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^z Institute Nacional del Cáncer   (Chile)

^aa SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; TAMOXIFEN; TRIPTORELIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; APPETITE DISORDER; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER SIZE; CONTROLLED STUDY; COPING BEHAVIOR; DIZZINESS; EARLY CANCER; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIAN FUNCTION SUPPRESSION; OVARIECTOMY; OVARY FUNCTION; PATIENT HISTORY OF CHEMOTHERAPY; PERSONALITY DISORDER; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SEXUALITY; SLEEP DISORDER; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINAL PRURITUS; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DRUG EFFECTS; LYMPH NODE METASTASIS; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; SELF REPORT;

ADULT; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; OVARY; PREMENOPAUSE; QUALITY OF LIFE; SELF REPORT; TAMOXIFEN; TRIPTORELIN PAMOATE;

EID: 84969989424     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.8675     Document Type: Article

References (28)

1. Pagani O, Regan MM, Walley BA, et al: Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371: 107-118, 2014
2. Francis PA, Regan MM, Fleming GF, et al: Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372:436-446, 2015
3. Hershman DL: Perfecting breast-cancer treatment: Incremental gains and musculoskeletal pains. N Engl J Med 372:477-478, 2015
4. Jankowitz RC, Puhalla S, Davidson NE: Should we embrace or ablate our urge to (ovarian) suppress? J Clin Oncol 32:3920-3922, 2014
5. Bernhard J, Luo W, Ribi K, et al: Patientreported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): A combined analysis of two phase 3 randomised trials. Lancet Oncol 16:848-858, 2015
6. Nystedt M, Berglund G, Bolund C, et al: Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 21:1836-1844, 2003
7. Berglund G, Nystedt M, Bolund C, et al: Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: A prospective randomized study. J Clin Oncol 19:2788-2796, 2001
8. Tevaarwerk AJ, Wang M, Zhao F, et al: Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): A trial of the Eastern CooperativeOncologyGroup. J ClinOncol 32:3948-3958, 2014
9. Coates AS, Winer EP, Goldhirsch A, et al: Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
10. Regan MM, Pagani O, Fleming GF, et al: Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. Breast 22:1094-1100, 2013
11. Bernhard J, Hürny C, Coates AS, et al: Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Ann Oncol 8:825-835, 1997
12. Butow P, Coates A, Dunn S, et al: On the receiving end. IV: Validation of quality of life indicators. Ann Oncol 2:597-603, 1991
13. Hürny C, Bernhard J, Coates A, et al: Responsiveness of a single-item indicator versus a multi-item scale: Assessment of emotional wellbeing in an international adjuvant breast cancer trial. Med Care 34:234-248, 1996
14. Hürny C, Bernhard J, Bacchi M, et al: The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer 1:200-208, 1993
15. Hürny C, van Wegberg B, Bacchi M, et al: Subjective health estimations (SHE) in patients with advanced breast cancer: An adapted utility concept for clinical trials. Br J Cancer 77:985-991, 1998
16. Bernhard J, Sullivan M, Hürny C, et al: Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84:1156-1165, 2001
17. Bernhard J, Maibach R, Thürlimann B, et al: Patients' estimation of overall treatment burden: Why not ask the obvious? J Clin Oncol 20:65-72, 2002
18. Day R, Ganz PA, Costantino JP, et al: Healthrelated quality of life and tamoxifen in breast cancer prevention: A report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17:2659-2669, 1999
19. Fallowfield L, Fleissig A, Edwards R, et al: Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19: 1885-1892, 2001
20. Ganz PA, Day R, Ware JE Jr, et al: Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 87:1372-1382, 1995
21. Greendale GA, Reboussin BA, Hogan P, et al: Symptom relief and side effects of postmenopausal hormones: Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 92:982-988, 1998
22. Alfano CM, McGregor BA, Kuniyuki A, et al: Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. Psychooncology 15:985-1000, 2006
23. Sloan JA, Dueck A: Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 14:73-96, 2004
24. Maunsell E, Goss PE, Chlebowski RT, et al: Quality of life in MAP.3 (Mammary Prevention 3): A randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol 32:1427-1436, 2014
25. Duric V, Stockler M: Patients' preferences for adjuvant chemotherapy in early breast cancer: A review of what makes it worthwhile. Lancet Oncol 2: 691-697, 2001
26. Duric VM, Fallowfield LJ, Saunders C, et al: Patients' preferences for adjuvant endocrine therapy in early breast cancer:What makes it worthwhile? Br J Cancer 93:1319-1323, 2005
27. Bober SL, Varela VS: Sexuality in adult cancer survivors: Challenges and intervention. J Clin Oncol 30:3712-3719, 2012
28. Schover LR: Premature ovarian failure and its consequences: Vasomotor symptoms, sexuality, and fertility. J Clin Oncol 26:753-758, 2008